Search
Enalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalRemoval of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril. … As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume
Categories: Agents Acting on the Renin-Angiotensin SystemrdESAT-6
go.drugbank.com/drugs/DB21906ApprovedrdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]
Ambrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAs an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Thonzonium
go.drugbank.com/drugs/DB09552ApprovedIt is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. … It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone.
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigationalof a peptidase-resistant formulation has allowed for its use as a viable treatment option in achondroplasia. … [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113]
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalIt was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].
Clofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalOn February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation
Synonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDELapyrium
go.drugbank.com/drugs/DB09376ApprovedLapyrium is a quaternary ammonium cation used as a surfactant, antistatic agent, and biocide in various cosmetic products [A19426]. It is commonly found formulated as lapyrium chloride.